John P Sabo
Overview
Explore the profile of John P Sabo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang F, Voelk C, Trampisch M, Rowland L, Schultz A, Sabo J
Basic Clin Pharmacol Toxicol
. 2018 Feb;
123(1):84-93.
PMID: 29427400
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus. In this single-centre, open-label, fixed-sequence, crossover study of 32 healthy adult male and female volunteers, subjects received either...
2.
Yong C, Gathe J, Knecht G, Orrell C, Mallolas J, Podzamczer D, et al.
HIV Clin Trials
. 2017 Dec;
18(5-6):189-195.
PMID: 29210627
Background: VERxVE data showed non-inferior virologic efficacy with extended release nevirapine (NVP-XR) dosed 400 mg once daily (QD) versus immediate release nevirapine (NVP-IR) 200 mg twice daily in a double-blind,...
3.
Sane R, Ramsden D, Sabo J, Cooper C, Rowland L, Ting N, et al.
Drug Metab Dispos
. 2015 Dec;
44(3):466-75.
PMID: 26684498
The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major metabolites, CD 6168 (formed via reduction by gut bacteria) and deleobuvir-acyl glucuronide...
4.
Anabwani G, Konigs C, Giaquinto C, Aslanyan S, Sabo J, Morrow J, et al.
Clin Infect Dis
. 2015 Apr;
61(3):476-9.
PMID: 25917636
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all...
5.
Zeuzem S, Soriano V, Asselah T, Gane E, Bronowicki J, Angus P, et al.
Antimicrob Agents Chemother
. 2014 Dec;
59(2):1282-91.
PMID: 25512403
Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet need. The HCV NS3/4A inhibitor, faldaprevir, was evaluated in combination with the nonnucleoside...
6.
Sabo J, Kort J, Ballow C, Kashuba A, Haschke M, Battegay M, et al.
J Clin Pharmacol
. 2014 Dec;
55(4):467-77.
PMID: 25449227
The potential inhibition of the major human cytochrome P450 (CYP) enzymes by faldaprevir was evaluated both in vitro and in clinical studies (healthy volunteers and hepatitis C virus [HCV] genotype...
7.
Sabo J, Lang B, Elgadi M, Huang F
Antimicrob Agents Chemother
. 2014 Nov;
59(1):514-9.
PMID: 25385099
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1. This study evaluated the effect of steady-state 240 mg...
8.
Chen L, Sabo J, Philip E, Rowland L, Mao Y, Latli B, et al.
Antimicrob Agents Chemother
. 2014 Oct;
59(1):25-37.
PMID: 25313217
The pharmacokinetics, mass balance, and metabolism of deleobuvir, a hepatitis C virus (HCV) polymerase inhibitor, were assessed in healthy subjects following a single oral dose of 800 mg of [(14)C]deleobuvir...
9.
Sabo J, Kort J, Ballow C, Haschke M, Battegay M, Fuhr R, et al.
Clin Infect Dis
. 2014 Aug;
59(10):1420-8.
PMID: 25091302
Background: Faldaprevir is a potent, once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor. Studies were performed to investigate potential drug interactions between faldaprevir and the commonly used antiretrovirals darunavir/ritonavir, efavirenz,...
10.
Giaquinto C, Anabwani G, Feiterna-Sperling C, Nuttall J, Mompati K, Konigs C, et al.
Pediatr Infect Dis J
. 2014 Jan;
33(7):e173-9.
PMID: 24378938
Background: To compare steady-state (ss) pharmacokinetic targets of nevirapine extended-release (NVP-XR) tablets once-daily (QD) with immediate-release (NVP-IR) tablet or oral suspension twice-daily in HIV-1-infected children and adolescents. Methods: Phase I,...